| scholarly article | Q13442814 |
| P50 | author | William Jeffery Sandborn | Q64364605 |
| P2093 | author name string | Fernando S Velayos | |
| P2860 | cites work | Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent | Q28191546 |
| Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 | ||
| Infliximab for the treatment of fistulas in patients with Crohn's disease | Q33860666 | ||
| Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease | Q33895677 | ||
| Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states | Q34033833 | ||
| New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia | Q34102237 | ||
| The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients | Q34544307 | ||
| Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety | Q35044577 | ||
| Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County | Q35596600 | ||
| Pneumocystis carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case and review of the literature | Q41576189 | ||
| Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. | Q41941349 | ||
| Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi | Q43515292 | ||
| Pneumocystis carinii pneumonia in patients with cancer. An increasing incidence | Q43633083 | ||
| Outcome of cytomegalovirus infections in patients with inflammatory bowel disease | Q43684194 | ||
| Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease | Q44477953 | ||
| Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine | Q44539555 | ||
| Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis | Q44576755 | ||
| Drug interaction between infliximab and azathioprine in patients with Crohn's disease. | Q44654800 | ||
| Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. | Q51044192 | ||
| A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | Q53964227 | ||
| Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease | Q57265459 | ||
| P433 | issue | 5 | |
| P921 | main subject | pneumonia | Q12192 |
| Pneumocystis carinii | Q2099992 | ||
| P304 | page(s) | 657-660 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Inflammatory Bowel Diseases | Q15749161 |
| P1476 | title | Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease | |
| P478 | volume | 10 |
| Q57471150 | A Practical Guide to the Safety and Monitoring of New IBD Therapies |
| Q37814549 | A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. |
| Q54394711 | An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. |
| Q37550670 | Biological therapy and dentistry: a review paper |
| Q40118082 | Clinical Manifestations and Prognostic Factors of Pneumocystis jirovecii Pneumonia without HIV. |
| Q35019838 | Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis |
| Q35692811 | Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease. |
| Q36438779 | Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease |
| Q36530539 | Increased dosage of infliximab is a potential cause of Pneumocystis carinii pneumonia |
| Q38335718 | Infection risk associated with anti-TNF-α agents: a review |
| Q40396288 | Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression |
| Q36162376 | Management of Pneumocystis pneumonia in patients with inflammatory disorders. |
| Q36171733 | Methods to avoid infections in patients with inflammatory bowel disease |
| Q44487841 | Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab |
| Q36789194 | Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases |
| Q43144371 | Pneumocystis jiroveci pneumonia and pneumomediastinum in an anti-TNFalpha naive patient with ulcerative colitis |
| Q45330600 | Pneumocystis jiroveci pneumonia in patients with inflammatory bowel disease: a survey of prophylaxis patterns among gastroenterology providers |
| Q40100993 | Pneumocystis jirovecii Pneumonia in Pediatric Inflammatory Bowel Disease: A Case Report and Literature Review |
| Q40080089 | Pneumocystis pneumonia complicating immunosuppressive therapy in Crohns disease: A preventable problem? |
| Q80089348 | Pneumocystis pneumonia during combined therapy of infliximab, corticosteroid, and azathioprine in a patient with Crohn's disease |
| Q36325180 | Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis |
| Q42846582 | Practical guidelines for the treatment of inflammatory bowel disease |
| Q36948496 | Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care |
| Q37690719 | Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study |
| Q92178119 | Risk Factors for Mortality in Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease |
| Q41502821 | Severe pneumocystis jiroveci pneumonia in a patient on temozolomide therapy: A case report and review of literature |
| Q38197891 | Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops |
| Q38062336 | The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease |
| Q93374087 | Therapy and Management of Pneumocystis jirovecii Infection |
Search more.